Webcasts

MDT Live October 2024

MDT Live March 2024

Our 2nd in the series where breast cancer clinicians come together to discuss HR+, HER2- early invasive breast cancer cases.

[MDT Live March 2024] Case 1 Premenopausal Node Negative Patient

[MDT Live March 2024] Case 2 Older Node Positive Patient

[MDT Live March 2024] Case 3 Postmenopausal N1 Patient

[MDT Live March 2024] Case 4 Postmenopausal Lobular Patient

[MDT Live March 2024] Case 5 Premenopausal Tubular Patient

[MDT Live March 2024] Case 6 Premenopausal T3 Patient

[MDT Live March 2024] Case 7 Male Breast Cancer Patient

[MDT Live March 2024] Case 8 Postmenopausal Node Positive Patient

[MDT Live March 2024] Case 9 Postmenopausal Node-Negative Patient

[MDT Live March 2024] Q&A and Close

[ESMO24] Evolving role of genomic assays in early breast cancer

Prof. Miguel Martin discusses the application of genomic assays in the neoadjuvant setting

[ESMO24] Tissue-based genomics to guide adjuvant therapy decisions

Prof. Janice Walshe discusses the impact of the introduction of genomic assays on clinical practice for both clinicians and patients.

[ESMO24] Introduction to MRD in breast cancer

Prof. Nicholas Turner provides a brief overview of the concept and terms related to molecular residual disease.

[ESMO24] Evolving role of MRD guided decision making in early breast cancer

Prof. Sherene Loi presented at ESMO 2024 an update on the current data and ongoing studies on molecular residual disease in early breast cancer.

[ESMO24] Optimizing the approach to MRD assay development

Rick Baehner provides a topline overview of ongoing research into the development of MRD assays.

MDT Live 2023

A panel of breast cancer clinicians come together to discuss HR+, HER2- early invasive breast cancer cases

Satellite Symposium, St Gallen 2023 - Improve patient care with genomic testing

Patient’s awareness and understanding of genomic testing - Professor Richard Simcock, UK

Satellite Symposium, St Gallen 2023 - Improve patient care with genomic testing

Identifying patients for Oncotype DX^® testing in my clinical practice - Professor Christos Markopoulos, Greece

The Oncotype DX^® Test: Evolution of UK Real World Outcomes Data

Miss Marianne Dillon, Consultant Oncoplastic Breast Surgeon from Swansea Bay University Health Board, Dr Wendy Taylor Consultant Clinical Oncologist at Newcastle upon Tyne Hospitals Trust, Miss P.G. Roy Consultant Oncoplastic and Reconstructive Breast Surgeon at Oxford University Hospitals NHS Trust, and Miss Hirah Rizki Consultant Oncoplastic Breast Surgeon from Imperial College Healthcare NHS Trust.

Follow the evidence to help guide chemotherapy decisions for early breast cancer patients

Dr Richard Simcock, Consultant Clinical Oncologist, Brighton and Sussex University Hospitals NHS Trust, and Dr David Hyams, Medical Director, Eisenhower Medical Center California, present a case study on the evidence to help guide chemotherapy decisions for early breast cancer patients.

Clinical utility of multigene assays in early breast cancer: Predictive tests

A presentation by Professor Christos Markopoulos from the University of Athens in Greece talking about the predictive ability of multigene assay in early breast cancer

Initial RxPONDER results in clinical practice: What will change?

Dr. Joan Albanell from the Hospital del Mar, Spain and and Dr. Mark Verrill from the Newcastle on Tyne Hospitals, UK discuss the initial RxPONDER results presented at SABCS 2020 and what impact this has on the clinical practice.

Initial RxPONDER results in clinical practice: What will change?

Prof. Stephen Chia from the University of British Columbia, Canada and Dr. Mark Verrill from the Newcastle on Tyne Hospitals, UK discuss the initial RxPONDER results presented at SABCS 2020 and what impact this has on the clinical practice.

Optimizing outcomes in early-stage breast cancer by tailoring the use of chemotherapy

Watch an expert panel at the 2019 St. Gallen International Breast Cancer Conference discuss evidence on how to guide adjuvant chemotherapy treatment decisions in HER2-, HR+, early-stage breast cancer patients.

The Oncotype DX Breast Recurrence Score assay in clinical practice

Prof. Maccon Keane from the Saolta University Health care Group at the University Hospital Galway in Ireland discusses the Oncotype DX Breast Recurrence Score^® assay evidence and in particular, the TAILORx landmark trial data.